Study subjects who completed study 216 will be eligible for participation in this study if:
- they received all 3 vaccinations with Hexavac during study 216 and the 4th Hexavac
vaccination outside the study
- the subject's parent(s)/legal guardian(s) understands the study and has provided
written informed consent for his/her child's study participation;
- a blood draw was performed after the 3rd vaccination during study 216.
Study subjects will be excluded from participation in this study if:
- they have received any vaccination containing hepatitis B, poliovirus or acellular
pertussis toxin antigens other than Hexavac
- they have received a blood transfusion or immunoglobulins during the period from 28
days prior to the 4th Hexavac vaccination until study entry
- they have received another vaccine during the period from 28 days prior to the 4th
Hexavac vaccination until study entry
- they are concurrently participating in or have participated in a clinical trial with
an investigational medicinal product since the completion of study 216
- they suffer from a disease (e.g. autoimmune disease) or were undergoing a form of
treatment that may be expected to influence immunological functions since the
completion of study 216
- they have received systemic corticosteroids during the period from 28 days prior to
the 4th Hexavac vaccination until study entry.